bauer9.jpg Kenneth Bauer
Columnista Experto de SIIC


Associate Professor of Medicine, Harvard Medical School.Chief, Hematology Section, VA Boston Healthcare System. Director, Thrombosis Clinical Research, Beth Israel Deaconess Medical Center, Boston, EE.UU.
EXPERIENCIA CLINICA CON FONDAPARINUX: UN NUEVO INHIBIDOR SINTETICO SELECTIVO DEL FACTOR XA
Columnista Experto de SIIC Kenneth Bauer en colaboración con


Fecha de aprobación: 21 de octubre, 2003
Primera edición en siicsalud: 28 de noviembre, 2003
Sección Artículos originales, subsección Expertos de Iberoamérica,
página /des/expertocompleto.php/20089  
Especialidad principal: Especialidad principalHematología

Especialidades relacionadas:
Cuidados Intensivos,Emergentología,Farmacología,Hematología,Medicina Farmacéutica,Medicina Interna,

  • Bauer KA, Hawkins DW, Peters PC, Petitou M, Herbert J-M, van Boeckel CAA, Meuleman DG. Fondaparinux, a synthetic pentasaccharide: The first in a new class of antithrombotic agents - the selective factor Xa inhibitors, Cardiovasc Drug Rev 20:37-52, 2002

  • Lassen MR, Bauer KA, Eriksson BI, Turpie AGG for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison, Lancet 359:1715-1720, 2002

  • Turpie AGG, Bauer KA, Eriksson BI, Lassen MR for the PENTATHLON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison, Lancet 359:1721-1726, 2002

  • Turpie AGG, Bauer KA, Eriksson BI, Lassen MR for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 randomized double-blind studies, Arch Intern Med 162:1833-1840, 2002

  • Eriksson BI, Bauer KA, Lassen MR, Turpie AGG for the Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for preventing venous thromboembolism after hip-fracture surgery, N Eng J Med 345:1298-1305, 2001

  • Bauer KA. The thrombophilias: Well-defined risk factors with uncertain therapeutic implications, Ann Intern Med 135:367-373, 2001

  • Bauer KA, Eriksson BI, Lassen MR, Turpie AGG for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery, N Eng J Med 345(345):, 2001


  • Kenneth Bauer

    ua40317
    Inicio/Home

    Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008